<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03861715</url>
  </required_header>
  <id_info>
    <org_study_id>Single-VS-multiple dose- AN007</org_study_id>
    <nct_id>NCT03861715</nct_id>
  </id_info>
  <brief_title>Single Follicular Dexarelix for LH Suppression During Ovarian Stimulation in Oocyte Donors.</brief_title>
  <official_title>Single Follicular Dexarelix, a New Long Acting GnRH- Antagonist for LH Suppression During Ovarian Stimulation in Oocyte Donors. A Randomised Control Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assisting Nature</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assisting Nature</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized prospective study in the evaluation of the long acting GnRH antagonist Degarelix
      against the classical multidose regime with Ganirelix for LH suppression during the
      follicular phase of an ovarian stimulation cycle in oocyte donors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized prospective study of the use of single dose of the long acting GnRH antagonist
      Degarelix for ovarian stimulation cycle in oocyte donors: Ovarian stimulation started on
      cycle Day2 with gonadotropins 175-300 IU and either GnRH antagonist single dose Degarelix or
      multidose GnRH antagonist Ganirelix initiated on Day6 of the stimulation cycle. Agonist
      triggering was used in both groups for oocyte maturation. Blastocyst formation rate and Live
      Birth Rates were estimated for both groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Live birth rate according to stimulation protocol</measure>
    <time_frame>Up to 38 weeks after embryo transfer</time_frame>
    <description>Live birth rate according to stimulation protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blastulation rate according to stimulation protocol</measure>
    <time_frame>Up to 6 days post oocyte retrieval</time_frame>
    <description>Blastulation rate according to stimulation protocol</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Infertility</condition>
  <condition>Premature Ovarian Failure</condition>
  <arm_group>
    <arm_group_label>Single Dose antagonist Degarelix</arm_group_label>
    <description>The blastocyst formation rate and live birth rates of patients who followed GnRH antagonist protocol with a single dose Degarelix.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multidose antagonist Ganirelix</arm_group_label>
    <description>The blastocyst formation rate and live birth rates of patients who followed GnRH antagonist protocol with multidose dose Ganirelix.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>live birth rate</intervention_name>
    <description>The blastulation rate and live birth rate according to the protocol of COS</description>
    <arm_group_label>Multidose antagonist Ganirelix</arm_group_label>
    <arm_group_label>Single Dose antagonist Degarelix</arm_group_label>
    <other_name>blastulation rate</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women 20-34 years old who follow COS with a single GnRH antagonist Degarelix or multidose
        GnRH antagonist Ganirelix.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 20-34 years;

          -  body mass index (BMI) 18-29kg/m2;

          -  regular menstrual cycle of 26-35 days,

          -  AMH levels age appropriate (â‰¥2.3 ng/ml)

          -  early follicular- phase serum concentration of FSH within normal limits (1-12 IU/l).

        Exclusion Criteria:

          -  women with diabetes and other metabolic disease

          -  women with hereditary genetic diseases;

          -  women with heart disease, QT prolongation,heart failure

          -  elevated liver enzymes, liver failure, hepatitis

          -  women with inflammatory or autoimmune disease

          -  abnormal karyotype;

          -  endometriosis stage III/IV;

          -  history of recurrent miscarriage;

          -  severe OHSS in a previous stimulation cycle or any contraindication for the use of
             gonadotrophins.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>34 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evaggelos Papanikolaou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assisting Nature</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Najdecki, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assisting Nature</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evaggelos Papanikolaou, MD,PhD</last_name>
    <phone>00302310424294</phone>
    <email>drvagpapanikolaou@yahoo.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assisting Nature</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57001</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evaggelos Papanikolaou, MD, PhD</last_name>
      <phone>00302310424294</phone>
      <email>papanikolaou@assistingnature.gr</email>
    </contact>
    <contact_backup>
      <last_name>Robert Najdecki, MD, PhD</last_name>
      <phone>00306936646464</phone>
      <email>rnajdecki@assistingnature.gr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>March 14, 2019</last_update_submitted>
  <last_update_submitted_qc>March 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assisting Nature</investigator_affiliation>
    <investigator_full_name>Papanikolaou Evaggelos</investigator_full_name>
    <investigator_title>Papanikolaou Evaggelos, MD, PhD, Fertility Specialist, Scientific Director at Assisting Nature IVF Clinic</investigator_title>
  </responsible_party>
  <keyword>antagonist protocol</keyword>
  <keyword>degarelix antagonist protocol</keyword>
  <keyword>degarelix</keyword>
  <keyword>IVF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

